Corpus Intelligence IC Memo — TAHOE FOREST HOSPITAL 2026-04-26 05:28 UTC
IC Memo — TAHOE FOREST HOSPITAL
Investment Committee Memorandum | CA | 25 beds | Grade B | EBITDA uplift $19.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TAHOE FOREST HOSPITAL

CCN 051328 | NEVADA, CA | 25 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

TAHOE FOREST HOSPITAL is a 25-bed suburban community hospital in NEVADA, CA with $264.3M in net patient revenue and a 13.0% operating margin. The hospital serves a payer mix of 33.6% Medicare, 5.8% Medicaid, and 60.6% commercial.

Thesis: Turnaround. Our ML models identify $19.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 13.0% to 20.3% (+736bps).

Net Revenue HCRIS$264.3M
Current EBITDA COMPUTED$34.2M
Operating Margin COMPUTED13.0%
Occupancy HCRIS59.7%
Revenue / Bed COMPUTED$10.6M
Net-to-Gross HCRIS50.4%
Distress Probability ML35.2%

2. Market Context & Competitive Position

414
CA Hospitals
-4.9%
State Median Margin
71
Comparable Hospitals

CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 13.0% places it above the state median. Among 71 size-comparable peers (12-50 beds), the median margin is -8.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 71 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TAHOE FOREST HOSPITAL (Target)CA25$264.3M13.0%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
ADVENTIST HEALTH REEDLEYCA49$187.1M1.8%
SUTTER DAVIS HOSPITALCA48$176.9M12.5%
ADVENTIST HEALTH UKIAH VALLEYCA50$173.4M-39.9%
ADVENTIST HEALTH CLEARLAKECA25$159.9M-6.3%
ST ELIZABETH COMMUNITY HOSPTICA49$159.2M3.5%
RIDGECREST REGIONAL HOSPITALCA25$149.6M-14.7%
HAZEL HAWKINS MEM. HOSPITALCA25$141.1M-16.7%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.6M+210bp18mo
Cost to Collect4.5%2.5%$5.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.2M+122bp9mo
Clean Claim Rate88.0%96.0%$169K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.6M
Cost to Collect
$5.3M
Denial Rate Reduction
$5.2M
A/R Days Reduction
$3.2M
Clean Claim Rate
$169K
Total EBITDA Uplift$19.5M
Current EBITDA$34.2M
+ RCM Uplift+$19.5M
Pro Forma EBITDA$53.7M
Current Margin13.0%
Pro Forma Margin20.3%
WC Released (1x)$10.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$52.7M$420.4M7.98x51.5%
Base (11x exit)10.0x11.0x$52.7M$479.6M9.10x55.5%
Bull Case9.0x11.0x$47.4M$560.9M11.83x63.9%
Bull (12x exit)9.0x12.0x$47.4M$625.9M13.20x67.5%
Bear Case11.0x10.0x$57.9M$306.0M5.28x39.5%
Bear (11x exit)11.0x11.0x$57.9M$355.4M6.13x43.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 71 hospitals with 12-50 beds
  • Same-state prioritization (n=72)
  • Comp margins: P25=-18.6% / P50=-8.3% / P75=1.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.